drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous T-cell therapy)
drug_description
Patient-derived TIL product consisting of >=5 x 10^9 autologous ex vivo-expanded T cells administered intravenously to mediate antigen-specific tumor cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous ex vivo‑expanded tumor-infiltrating T cells that recognize patient-specific tumor antigens via native TCRs and kill tumor cells through cytotoxic effector functions (perforin/granzyme and cytokines); conditioning/IL-2 support engraftment and persistence.
drug_name
LM103 (autologous tumor-infiltrating lymphocytes)
nct_id_drug_ref
NCT05971576